Preclinical development of mecbotamab vedotin (BA3011), a novel, AXL-specific conditional active biologic antibody–drug conjugate
Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody–drug conjugate
Ozuriftamab Vedotin (BA3021), a Conditionally Binding ROR2-ADC in Patients with Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck: Antitumor Activity Observed Among Patients with Both HPV Related and HPV-Negative Cancers
Exploratory Analysis of Overall Survival among Non-Small Cell Lung Cancer (NSCLC) Patients with Mutated KRAS in a Phase 2 Trial of Mecbotamab Vedotin (CAB-AXL-ADC)
Updated Results from a Study of Evalstotug (BA3071), an Anti–CTLA-4 Conditionally Active Biologic
Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC
BA3361, a NextGen CAB ADC Targeting Nectin4
Updated Phase 1 and preliminary Phase 2 results from a study of evalstotug (BA3071), an anti–CTLA-4 conditionally active biologic, with or without nivolumab, in advanced solid tumors
Evalstotug (BA3071): A potent conditionally active biologic (CAB) anti–CTLA-4 antibody designed to enable high exposures, extended dosing, and reduced immune-mediated toxicity.
Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck